Match!
Magdalena Wladysiuk
Health careStakeholderReimbursementMedicinePharmacology
9Publications
7H-index
212Citations
What is this?
Publications 9
Newest
#1Evelien Moorkens (Katholieke Universiteit Leuven)H-Index: 3
#2Arnold G. Vulto (Erasmus University Medical Center)H-Index: 40
Last. Steven Simoens (Katholieke Universiteit Leuven)H-Index: 30
view all 34 authors...
markdownabstract__Background__ Across European countries, differences exist in biosimilar policies, leading to variations in uptake of biosimilars and divergences in savings all over Europe. __Objectives__ The aim of this article is to provide an overview of different initiatives and policies that may influence the uptake of biosimilars in different European countries. Recommendations will be formulated on how to create sustainable uptake. __Methods__ An overview of policies on biosimilars was o...
29 CitationsSource
#1Winnie de Bruijn (UU: Utrecht University)H-Index: 1
#2Cristina IbáñezH-Index: 2
Last. Brian Godman (Strathclyde Institute of Pharmacy and Biomedical Sciences)H-Index: 39
view all 40 authors...
Background: Infection with the Hepatitis C Virus (HCV) is a widespread transmittable disease with a diagnosed prevalence of 2.0%. Fortunately, it is now curable in most patients. Sales of medicines ...
19 CitationsSource
#1Brian Godman (Strathclyde Institute of Pharmacy and Biomedical Sciences)H-Index: 39
#2Rickard E. Malmström (Karolinska University Hospital)H-Index: 22
Last. Lars L. Gustafsson (Karolinska University Hospital)H-Index: 53
view all 36 authors...
Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are effectiveness, safety and/ or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular atrial fibrillation (AF), exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal ...
20 CitationsSource
#1Brian Godman (FIOCRUZ: Oswaldo Cruz Foundation)H-Index: 39
#2Alexander E Finlayson (Weston Education Centre)H-Index: 16
Last. Lars L. Gustafsson (Karolinska University Hospital)H-Index: 53
view all 45 authors...
Considerable variety in how patients respond to treatments, driven by differences in their geno- and/ or phenotypes, calls for a more tailored approach. This is already happening, and will accelerate with developments in personalized medicine. However, its promise has not always translated into improvements in patient care due to the complexities involved. There are also concerns that advice for tests has been reversed, current tests can be costly, there is fragmentation of funding of care, and ...
58 CitationsSource
#1Rickard E. Malmström (Karolinska University Hospital)H-Index: 22
#2Brian Godman (KI: Karolinska Institutet)H-Index: 39
Last. Lars L. Gustafsson (KI: Karolinska Institutet)H-Index: 53
view all 47 authors...
Background: There are potential conflicts between authorities and companies to fund new premium priced drugs especially where there are safety and/ or budget concerns. Dabigatran, a new oral anticoagulant for the prevention of stroke in patients with non-valvular AF, exemplifies this issue. Whilst new effective treatments are needed, there are issues in the elderly with dabigatran due to variable drug concentrations, no known antidote and dependence on renal elimination. Published studies have s...
53 CitationsSource
‘HTA for Crisis’ – 7th Evidence-Based Health Care Symposium organized by the Central and Eastern European Society for Technology Assessment in HealthcareKrakow, Poland, 8–9 October 2012The Central and Eastern European Society of Technology Assessment in Health Care was founded in Krakow, Poland in 2003. On October 8th and 9th, the 7th symposium took place titled ‘HTA for Crisis’. This meeting was attended by over 250 decision makers, evidence-based specialists, healthcare managers, commercial co...
1 CitationsSource
Last. Alan HaycoxH-Index: 36
view all 6 authors...
9 Citations
#2Katarzyna SzabertH-Index: 3
Last. Alan Haycox (University of Liverpool)H-Index: 36
view all 6 authors...
Pressures to contain pharmaceutical expenditure have led to increased prescribing and dispensing of generic drugs in addition to low prices for generics. Atypical antipsychotics are prescribed for schizophrenia leading to resource pressures with their higher acquisition costs than typical antipsychotics. Drug costs can be reduced once multiple sources are available. However, this must be balanced against possible efficacy, safety and compliance concerns given the high cost of relapses for patien...
23 CitationsSource
#2Katarzyna SzabertH-Index: 3
Last. Alan HaycoxH-Index: 36
view all 6 authors...
Pressures to contain pharmaceutical expenditure have led to increased prescribing and dispensing of generic drugs in addition to low prices for generics. Atypical antipsychotics are prescribed for schizophrenia leading to resource pressures with their higher acquisition costs than typical antipsychotics. Drug costs can be reduced once multiple sources are available. However, this must be balanced against possible efficacy, safety and compliance concerns given the high cost of relapses for patien...
1